A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Eli Lilly should easily beat the market again in 2025, as it did in 2024. Summit Therapeutics awaits a potentially huge ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Purdue University has launched an online version of its Master of Business and Technology degree program. Purdue says the degree differs from a traditional MBA, and it leverages emerging technology to ...

Indiana Landmarks is currently accepting applications for two funds created to honor the legacy of a Brazil native and Eli ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are two important insights from that call that should excite investors about ...

Obesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) have found themselves in two contrasting positions as Robert F. Kennedy Jr., a leading critic of weight loss drugs, takes the helm of the ...

WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...